Blood-Brain Barrier: Bridging Options for Drug Discovery and Development

By Allan B. Haberman, PhD

1. Please classify your organization

2. Please describe the product area/areas that best describes your organization’s major involvement in CNS drugs

3. Has your involvement in CNS drugs changed over the past 4 years?

4. How many CNS drugs do you expect to launch in 2008 or 2009?

5. How many CNS drugs do you have in the pipeline (preclinical to preregistration)?

6. Which indications do your pipeline drugs attempt to address?

7. Which do you see as the biggest bottleneck in successful development of your CNS drugs?

8. Do you have specific R&D programs in crossing the BBB?

9. If yes, do you have programs in the following, with respect to designing small-molecule drugs that cross the BBB:

10. Do you have programs in the following, with respect to designing large-molecule drugs (peptides, proteins, nucleic acids) that cross the BBB:

11. Are you developing technologies to enable BBB R&D:

12. Are you using imaging methods to evaluate brain penetration and target occupancy of drugs: